(Q34519117)

2 August 2017

1 reference

title

Evolving therapies for the treatment of chronic hepatitis B virus infection (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

William Delaney

1

1 reference

2 August 2017

Angeline Bartholomeusz

series ordinal

2

1 reference

2 August 2017

Stephen A Locarnini

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

11

1 reference

2 August 2017

2

1 reference

2 August 2017

169-187

1 reference

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Hepatitis B virus biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

The role of envelope proteins in hepatitis B virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

α-Glucosidase inhibitors as potential broad based anti-viral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Glycosylation inhibitors in biology and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Characterization of hepatitis B virus core mutants that inhibit viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Significant interference with hepatitis B virus replication by a core-nuclease fusion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Antisense oligodeoxynucleotides as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Inhibition of hepatitis B virus by antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Simple RNA enzymes with new and highly specific endoribonuclease activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Intracellular application of hairpin ribozyme genes against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Prospects for active immunotherapies for hepatitis B virus chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.2.169

10.1517/13543784.11.2.169

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference